M9657, a tumor-targeted anti-CD137 agonist, induced significant antitumor immunity in combination with anti-PD-1 antibody

被引：0
|
作者：
Xu, Chunxiao
Yalavarthi, Sireesha
Zhang, Hong
Gundra, Uma Mahesh
Bourin, Clotilde
Helming, Laura
机构：
来源：
CANCER RESEARCH | 2023年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5305
引用
收藏
页数：2
相关论文
共 50 条
  • [1] M9657, A NOVEL TUMOR-TARGETED CONDITIONAL ANTI-CD137 AGONIST DISPLAYS MSLN-DEPENDENT ANTI-TUMOR IMMUNITY
    Xu, Chunxiao
    Rabinovich, Brain
    Deshpande, Amit
    Zhou, Xueyuan
    Pipp, Frederic Christian
    Schweickhardt, Rene
    Webb, Lindsay
    Yalavarthi, Sireesha
    Bourin, Clotilde
    Ghatak, Payel
    Safi, Barroq
    Wollerton, Francisca
    Brewis, Neil
    Munoz-Olaya, Jose
    Belousova, Natalya
    Alimzhanov, Marat
    Hubensack, Martina
    Halle, Joern-Peter
    Blaukat, Andree
    Moisan, Jacques
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A792 - A792
  • [2] M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
    Xu, Chunxiao
    Zhou, Xueyuan
    Webb, Lindsay
    Yalavarthi, Sireesha
    Zheng, Wenxin
    Saha, Somdutta
    Schweickhardt, Rene
    Soloviev, Maria
    Jenkins, Molly H.
    Brandstetter, Susanne
    Belousova, Natalya
    Alimzhanov, Marat
    Rabinovich, Brian
    Deshpande, Amit M.
    Brewis, Neil
    Helming, Laura
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (02) : 195 - 213
  • [3] Anti-tumor immunity of M9657, a conditional CD137 immune agonist, is correlated with mesothelin expression on tumor cells
    Xu, Chunxiao
    Zhou, Xueyuan
    Yalavarthi, Sireesha
    Schweickhardt, Rene
    Blaukat, Andree
    Helming, Laura
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
    Upadhyaya, Punit
    Lahdenranta, Johanna
    Hurov, Kristen
    Battula, Sailaja
    Dods, Rachel
    Haines, Eric
    Kleyman, Marianna
    Kristensson, Julia
    Kublin, Jessica
    Lani, Rachid
    Ma, Jun
    Mudd, Gemma
    Repash, Elizabeth
    Van Rietschoten, Katerine
    Stephen, Tom
    You, Fanglei
    Harrison, Helen
    Chen, Liuhong
    McDonnell, Kevin
    Brandish, Philip
    Keen, Nicholas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [5] Lenvatinib enhances antitumor immunity of anti-PD-1 antibody
    Yu Kato
    International Journal of Clinical Oncology, 2025, 30 (4) : 666 - 673
  • [6] Combination of anti-CD73 and agonistic anti-CD137 antibody therapy leads to tumor regression
    Chen, Siqi
    Zhang, Bin
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [7] PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
    Lim, Michael
    Ye, Xiaobu
    Nabors, Burt
    Piotrowski, Anna F.
    Fisher, Joy
    Desideri, Serena
    Sims, Megan
    Wen, Patrick
    Grossman, Stuart A.
    NEURO-ONCOLOGY, 2017, 19 : 31 - 31
  • [8] Tumor responses of anti-CD137 agonist antibody activated by elevated extracellular ATP in tumor microenvironment
    Sakurai, Mika
    Narita, Yoshinori
    CANCER SCIENCE, 2022, 113
  • [9] Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.
    Lim, Michael
    Ye, Xiaobu
    Piotrowski, Anna F.
    Desai, Arati Suvas
    Ahluwalia, Manmeet Singh
    Walbert, Tobias
    Fisher, Joy D.
    Desideri, Serena
    Belcaid, Zineb
    Jackson, Christina
    Nabors, Louis B.
    Wen, Patrick Y.
    Grossman, Stuart A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
    Lim, Michael
    Ye, Xiaobu
    Nabors, L. Burt
    Piotrowski, Anna
    Ahluwalia, Manmeet
    Desai, Arati
    Walbert, Tobias
    Fisher, Joy
    Desideri, Serena
    Sims, Megan
    Wen, Patrick
    Grossman, Stuart
    NEURO-ONCOLOGY, 2018, 20 : 5 - 5
12345